19031-43-7Relevant articles and documents
FIBROSIS INHIBITOR
-
, (2008/06/13)
Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.
A Method for the Regioselective Synthesis of 2-Methyl-5-nitro- and 2-Methyl-8-nitroquinoxalines, and the Application of Proton-Coupled 13C NMR to Assign their Structure
Grivas, Spiros,Tian, Wei,Andersson, Rolf
, p. 2701 - 2712 (2007/10/02)
The regioselective synthesis of the title compounds and some of their bromo and chloro derivatives from the condensation of 3-nitro-1,2-benzenediamines with methylglyoxal (pyruvic aldehyde) is described.The splitting patterns at the bridgehead carbons in the proton-coupled 13C NMR spectra are proposed as a useful method for the distinction of the isomers formed after such a condensation.The previously reported erroneous structures of 5-amino, 5-bromo- and 5-chloro-2-methylquinoxalines are corrected.